Rituximab Therapy for Steroid-Refractory Chronic Graft Versus Host Disease
An Open Label, Phase I/II Trial of Rituximab Therapy for Steroid-Refractory Chronic Graft vs. Host Disease
研究概览
详细说明
Patients will receive rituximab intravenously one time per week for four consecutive weeks. Once therapy is completed, the patient will have weekly visits with their physician for four more weeks, at which they will complete a simple questionnaire designed to evaluate the severity of chronic graft versus host disease.
At the end of the eighth week on the study (4 weeks of study treatment and 4 weeks of observation), patients will be evaluated to determine whether their chronic graft versus host disease (GVHD) has resolved.
If chronic graft versus host disease has resolved entirely, the patient will be monitored for the remainder of the year.
If after the initial eight weeks on the study the patient still has symptoms or signs of GVHD, they may receive a second four week study treatment.
If the patients' chronic GVHD reappears after receiving either one or two courses of rituximab, a third and final four week course of medication can be given provided it has been at least eight weeks since the last dose.
Blood tests will be performed at the beginning of the study, after 8 weeks on the study, after 16 weeks on the study and at the end of 1 year.
研究类型
注册 (实际的)
阶段
- 阶段2
- 阶段1
联系人和位置
学习地点
-
-
Massachusetts
-
Boston、Massachusetts、美国、02115
- Dana-Farber Cancer Institute
-
Boston、Massachusetts、美国、02115
- Brigham and Women's Hospital
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Recipients of matched related, matched unrelated, or mismatched stem cell transplantation
- At least 180 days since allogeneic stem cell transplantation procedure
- Patients must have steroid-refractory chronic GVHD, defined as having persistent signs and symptoms despite the use of prednisone
- Stable dose of corticosteroids for 4 weeks prior to enrollment
- Adequate bone marrow function: absolute neutrophil count (ANC) > 500/mm; platelets > 20,000 ul
- Adequate renal function: creatinine < 3.0 mg/dl
- Adequate hepatic function: bilirubin < 3.0 mg/dl; AST < 90 IU
Exclusion Criteria:
- Prednisone requirement greater than 2 mg/kg/day or equivalent
- Known life-threatening sensitivity to rituximab or other anti-B cell antibody.
- Prior exposure to any new immunosuppressive medication in the preceding 4 weeks prior to enrollment.
- Active, uncontrolled infection
- Evidence of natural exposure to hepatitis B or C.
- Active malignant disease relapse
- Donor lymphocyte infusion within the preceding 100 days.
- Life expectancy of less than 3 months.
- Pregnancy or lactation
- Evidence of HIV seropositivity
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:单组作业
- 屏蔽:无(打开标签)
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
To determine the safety and efficacy of up to three four week courses of rituximab in steroid-refractory chronic GVHD
大体时间:2 years
|
2 years
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
To determine the effects of rituximab therapy on quality of life of patients with steroid-refractory GVHD
大体时间:2 years
|
2 years
|
合作者和调查者
调查人员
- 首席研究员:Corey S. Cutler, MD, MPH、Dana-Farber Cancer Institute
出版物和有用的链接
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.